Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Releases

  • Webcast Image Webcast
    Spring Bank to Discuss Inarigivir Data Presented at the International Liver Congress™ (EASL 2019)  (Replay)
    Friday, April 12, 2019 8:00 am EDT
Toggle Summary Spring Bank Pharmaceuticals Reports First Quarter 2019 Financial and Operational Results and Provides Corporate Update
ACHIEVE trial completed – inarigivir HBsAg reduction comparable to interferon but with significantly better tolerability profile Phase 2 co-administration study of inarigivir + nucleotide analogue fully enrolled – top-line results expected 2H’19 Study results to be presented at Science of HBV Cure
Toggle Summary Spring Bank Announces Positive Results from the Recently Completed Phase 2 Chronic Hepatitis B ACHIEVE Trial and Additional Inarigivir Studies
Consistent reduction in HBV DNA demonstrated with higher inarigivir doses including in high viral burden HBeAg-positive patients 26% HBsAg responder population for all inarigivir doses showed mean HBsAg change of 0.8log 10 with a range of 0.5log 10 - 1.4log 10 Inarigivir 400mg rapidly and uniformly
Toggle Summary Spring Bank to Host a Conference Call to Discuss Inarigivir Data Presented at the International Liver Congress™ (EASL 2019)
Conference call to be held on Friday, April 12 at 8:00am EDT HOPKINTON, Mass. , April 10, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases
Toggle Summary Spring Bank Announces Inarigivir Abstracts Accepted for Oral and Poster Presentations at The International Liver Congress™ (EASL 2019)
Full inarigivir (IRIG) 200mg cohort results to be presented as a late breaker oral presentation  at General Session II and Award Ceremony I Poster presentation to describe the antiviral activity of IRIG in HBV clinical isolates consisting of nucleoside/CpAM-resistant variants HOPKINTON, Mass.
Toggle Summary Spring Bank Pharmaceuticals to Participate in Jefferies 2019 HBV Summit
HOPKINTON, Mass. , March 14, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Nezam Afdhal ,
Toggle Summary Spring Bank Pharmaceuticals Reports 2018 Fourth Quarter and Full-Year Financial Results and Corporate Highlights
Conference Call to be Held at 8:00 am Eastern Time Inarigivir Late-Breaker Abstract Accepted for Oral Presentation at EASL The International Liver Congress 2019 HOPKINTON, Mass. , March 11, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical
Toggle Summary Spring Bank to Host Conference Call to Discuss Fourth Quarter and Fiscal Year 2018 Results on Monday, March 11
Conference Call to be Held at 8:00am Eastern Time HOPKINTON, Mass. , March 04, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain
Toggle Summary Spring Bank Pharmaceuticals Appoints Atif Abbas, M.D., as Vice President, Head of Oncology & Immunology Clinical Development
HOPKINTON, Mass. , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced the appointment of Atif
Toggle Summary Spring Bank Pharmaceuticals Appoints Scott Smith as Chairman of the Board
HOPKINTON, Mass. , Dec. 18, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced it has appointed
Toggle Summary Spring Bank Pharmaceuticals Hosts R&D Day on Pipeline of Novel Immunomodulatory Therapeutics
R&D Day to take place today, December 6, 2018, in New York City and will be webcast live HOPKINTON, Mass. , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral